Redwire Corporation (NYSE:RDW), a global leader in space and defense technology solutions, today announced that NASA has awarded the company an additional $4 million to support new drug development investigations on the International Space Station (ISS) using Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology. This additional funding expands an existing task order under a $25 million, five-year indefinite-delivery/indefinite-quantity contract through NASA's In Space Production Applications (InSPA) program.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.